Other therapies:

Convalescent plasma (CP) is available at SHC, however, per the NIH guidelines, there are insufficient data to recommend either for or against its use for COVID-19. CP should not be considered the standard of care for the treatment of patients with COVID-19, but may be considered in immunocompromised patients. We do not recommend use of baricitinib-remdesivir when corticosteroids and/or tocilizumab can be used.

* Note Strongyloides IgG should be checked for people who were born or have resided in a developing country or an endemic area of the US. In case of dexamethasone shortage can substitute prednisone 40 mg, methylprednisolone 32 mg or hydrocortisone 160 mg

** Remdesivir may be ordered without ID approval in hospitalized patients with COVID-19 on supplemental oxygenation but not mechanical ventilation or ECMO for a maximum of 5 days of therapy. For patients on mechanical ventilation or therapy extension beyond 5 days, page ID team for approval (first dose may be given per primary team prior to COVID-ID approval to avoid treatment delay).